[{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ildong Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Ildong Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Akums Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akums Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Lifesciences \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Lasmiditan Succinate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Reyvow-Generic (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine.

                          Product Name : Reyvow-Generic

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          May 01, 2024

                          Lead Product(s) : Lasmiditan

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Reyvow (lasmiditan hemisuccinate) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.

                          Product Name : Reyvow

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 25, 2022

                          Lead Product(s) : Lasmiditan

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Eli Lilly

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Rayvow will be available as 50 mg, 100 mg and 200 mg film-coated tablets. The active substance of Rayvow is lasmiditan, a 5-hydroxytriptamine 1F (5-HT1F) receptor agonist (ATC code: N02CC), effecting a decrease of neuropeptide release and an inhibition o...

                          Product Name : Reyvow

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          June 23, 2022

                          Lead Product(s) : Lasmiditan

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Reyvow (lasmiditan hemisuccinate) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.

                          Product Name : Reyvow

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 21, 2022

                          Lead Product(s) : Lasmiditan

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Under the agreement, Eli Lilly Japan will hold authorisation for marketing lasmiditan succinate, similar to the humanized anti-CGRP monoclonal antibody Emgality (galcanezumab), and Daiichi Sankyo will take charge of its distribution and sales after marke...

                          Product Name : Reyvow

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          August 30, 2021

                          Lead Product(s) : Lasmiditan

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Daiichi Sankyo

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Adults who took REYVOW C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 4.6 times greater odds, respectively, of achieving pain freedom at 2 hours compared to those taking placebo, according to results from the recently completed P...

                          Product Name : Reyvow

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          November 09, 2020

                          Lead Product(s) : Lasmiditan

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Reyvow (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches.

                          Product Name : Reyvow

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          June 10, 2020

                          Lead Product(s) : Lasmiditan

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Reyvow (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches.

                          Product Name : Reyvow

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 31, 2020

                          Lead Product(s) : Lasmiditan

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank